Reducing Cancer Health Disparities in Detroit

减少底特律的癌症健康差异

基本信息

批准号：
10289601
负责人：
GEROLD BEPLER
金额：
$ 99.34万
依托单位：
WAYNE STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-20 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10289601
关键词：
Address African American Area Automobile Driving Awareness Behavioral Biological Cancer Biology Cancer Burden Cancer Patient Censuses Cities Clinical Clinical Trials Communities Community Outreach Comprehensive Cancer Center County Development Disease Enrollment Ensure Environment Evaluation Face Foundations Funding Future Genetic Genetic Diseases Genetic Medicine Genomics Guidelines Home Household Immune Immune checkpoint inhibitor Immunotherapy Income Individual Institutes Malignant Neoplasms Malignant neoplasm of lung Medically Underserved Area Mentors Michigan Minority Groups Modeling Molecular Genetics New Agents Outcome Participant Patients Population Population Heterogeneity Poverty Quality of life Race Reporting Research Research Personnel Research Project Grants Scientist Specialized Program of Research Excellence Structure Time Translating Translational Research Translations Tumor Markers Underserved Population United States Health Resources and Services Administration Universities Work base cancer health disparity cancer prevention cancer site cancer therapy clinical application community engagement disparity reduction health disparity high risk immune-related adverse events improved innovation member metropolitan novel marker patient engagement patient population precision medicine programs racial disparity racial diversity recruit response side effect standard care standard of care treatment response tumor

项目摘要

Overall Program Summary This application for Feasibility and Planning Studies of a P20 Specialized Program of Research Excellence (SPORE) to Investigate Cancer Health Disparities will address racial disparities in metropolitan Detroit, a uniquely important underserved population where great cancer disparities exist. The application includes two scientific projects focused on treatment with immune checkpoint inhibitors (ICIs) now being used in the standard of care setting for lung cancer, an Administrative Core, a Biospecimen Core, a Patient and Community Engagement Core, and a Developmental Research Program. The decision to use ICIs relies heavily on prior treatment response and imperfect tumor biomarkers, and immune-related adverse events (irAEs) dictate continued therapy, and ultimately outcomes, yet little is known about what factors drive disease course in racially diverse populations. The Overall Aim 1 of this Program is to accelerate translational research to reduce health disparities in lung cancer outcomes by: a) characterizing race-specific immune profiles with respect to the tumor environment and host genetic background to determine their contribution to response to ICIs (Project 1); and b) characterizing patient-reported side effects, quality of life, and irAEs in a racially diverse group of lung cancer patients and identifying the individual, behavioral, molecular/genetic and disease-specific determinants of these end points (Project 2). The Overall Aim 2 is to strengthen the existing programmatic structure to encourage translational research into the biology of cancer health disparities, achieve full P50 SPORE funding, and ultimately reduce cancer health disparities by: a) expanding our Cancer Biology of Health Disparities initiative, facilitating use of biospecimens from KCI's racially diverse population, and funding Developmental Research Projects; b) mentoring investigators in cancer health disparities; and c) expanding our community outreach and engagement efforts through a robust Patient and Community Engagement Core (PCEC) to support recruitment and retention of diverse study participants and dissemination of research project progress and findings to participants and lay audiences. This P20 application will enable clinical, basic and population scientists to translate relevant, high-impact scientific discoveries in diverse patients to reduce racial disparities in cancer outcomes, moving towards a more race-inclusive, equity-focused precision medicine approach to cancer treatment and prevention.

整体计划概要 P20 卓越研究专业计划的可行性和规划研究申请 (SPORE) 调查癌症健康差异将解决底特律大都市的种族差异存在巨大癌症差异的独特重要的服务不足人群。该应用程序包括两个专注于免疫检查点抑制剂（ICIs）治疗的科学项目现已在标准中使用肺癌护理环境、行政核心、生物样本核心、患者和社区参与核心和发展研究计划。使用 ICI 的决定在很大程度上依赖于先前的治疗反应和不完善的肿瘤生物标志物以及免疫相关不良事件 (irAE) 决定了持续治疗以及最终结果，但对于种族间疾病进程的驱动因素知之甚少不同的人群。该计划的总体目标 1 是加速转化研究以减少健康通过以下方式确定肺癌结果的差异：a) 描述肿瘤的种族特异性免疫特征环境和宿主遗传背景，以确定它们对 ICI 反应的贡献（项目 1）；和 b) 描述不同种族肺癌患者报告的副作用、生活质量和 irAE 的特征患者并确定这些患者的个体、行为、分子/遗传和疾病特异性决定因素终点（项目 2）。总体目标 2 是加强现有的计划结构，以鼓励癌症健康差异生物学的转化研究，获得 P50 SPORE 全额资助，以及通过以下方式最终减少癌症健康差异：a) 扩大我们的癌症健康差异生物学倡议，促进使用 KCI 不同种族人群的生物样本，并资助发展研究项目； b) 指导研究人员了解癌症健康差异； c) 扩大我们的社区外展范围通过强大的患者和社区参与核心 (PCEC) 来支持招募保留不同的研究参与者，并将研究项目的进展和结果传播给参与者和普通观众。该 P20 应用程序将使临床、基础和人口科学家能够将相关的、具有高影响力的科学发现应用于不同的患者，以减少癌症方面的种族差异结果，朝着更具种族包容性、注重公平的精准医学方法治疗癌症治疗和预防。